PMID- 34908832
OWN - NLM
STAT- MEDLINE
DCOM- 20220322
LR  - 20220429
IS  - 1178-2005 (Electronic)
IS  - 1176-9106 (Print)
IS  - 1176-9106 (Linking)
VI  - 16
DP  - 2021
TI  - Factors Associated with Reduction of Sedentary Time Following 
      Tiotropium/Olodaterol Therapy in Treatment-Naive Chronic Obstructive Pulmonary 
      Disease.
PG  - 3297-3307
LID - 10.2147/COPD.S338560 [doi]
AB  - BACKGROUND: Prolonged sedentary behavior is associated with worse prognosis in 
      patients with chronic obstructive pulmonary disease (COPD). Our previous study 
      found that first-line dual therapy with tiotropium/olodaterol significantly 
      reduces sedentary time compared to tiotropium monotherapy in Japanese patients 
      with treatment-naive COPD, although the characteristics of responders to 
      dual-therapy versus monotherapy for COPD are still unclear. METHODS: Patients 
      with treatment-naive COPD were randomized to receive either tiotropium or 
      tiotropium/olodaterol treatment for 12 weeks. Physical activity was assessed 
      using a triaxle accelerometer for 2 weeks before and after treatment. This 
      analysis focused on the change in sedentary time, indicated by physical activity 
      of 1.0-1.5 metabolic equivalents (METs), with stratification for the following 
      factors: age, body mass index (BMI), pulmonary function, COPD assessment test 
      (CAT), the 6-minute walk distance (6MWD), and physical activity level at study 
      entry. RESULTS: Thirty-five patients received tiotropium/olodaterol and 34 
      patients received tiotropium. In patients with lower inspiratory capacity at 
      study entry, a significant reduction in sedentary time was observed in the 
      tiotropium/olodaterol group compared with the tiotropium group (Tio: -12.8 +/- 13.5 
      min, Tio/Olo: -65.1 +/- 21.0 min, mean difference, -52.2 min, 95% CI -103.6 to 
      0.88, p = 0.046). In patients with a shorter duration of physical activity of >/=2 
      METs at study entry, a significant reduction of sedentary time was observed in 
      the tiotropium/olodaterol group compared with the tiotropium group (Tio: -3.3 +/- 
      17.5 min, Tio/Olo: -72.9 +/- 23.1 min, mean difference, -69.7 min, 95% CI -128.7 to 
      -10.6, p = 0.02). There were no differences in terms of age, BMI, CAT score, 
      6MWD, FEV1, FVC, VC, and physical activity of 1.0-1.5 METs and >/=3.0 METs. 
      CONCLUSION: This study showed that COPD patients with lower inspiratory capacity 
      or shorter active time of >/=2.0 METs at study entry are likely to exhibit 
      significantly greater reduction in sedentary time with tiotropium/olodaterol 
      treatment.
CI  - (c) 2021 Takahashi et al.
FAU - Takahashi, Koichiro
AU  - Takahashi K
AUID- ORCID: 0000-0003-0461-5072
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
FAU - Tashiro, Hiroki
AU  - Tashiro H
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
FAU - Tajiri, Ryo
AU  - Tajiri R
AD  - Clinical Research Center, Saga University Hospital, Faculty of Medicine, Saga 
      University, Saga, Japan.
FAU - Takamori, Ayako
AU  - Takamori A
AD  - Clinical Research Center, Saga University Hospital, Faculty of Medicine, Saga 
      University, Saga, Japan.
FAU - Uchida, Masaru
AU  - Uchida M
AUID- ORCID: 0000-0002-2474-5619
AD  - Division of Internal Medicine, Japan Community Health Care Organization Saga 
      Central Hospital, Saga, Japan.
FAU - Kato, Go
AU  - Kato G
AD  - Division of Respiratory Medicine, Saga Prefectural Medical Center Koseikan, Saga, 
      Japan.
FAU - Kurihara, Yuki
AU  - Kurihara Y
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
FAU - Sadamatsu, Hironori
AU  - Sadamatsu H
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
FAU - Kinoshita, Takashi
AU  - Kinoshita T
AD  - Division of Respirology, Neurology, and Rheumatology, Department of Medicine, 
      Kurume University School of Medicine, Fukuoka, Japan.
FAU - Yoshida, Makoto
AU  - Yoshida M
AUID- ORCID: 0000-0001-6367-3470
AD  - Division of Respiratory Medicine, National Hospital Organization Fukuoka 
      Hospital, Fukuoka, Japan.
FAU - Kawaguchi, Atsushi
AU  - Kawaguchi A
AD  - Clinical Research Center, Saga University Hospital, Faculty of Medicine, Saga 
      University, Saga, Japan.
AD  - Education and Research Center for Community Medicine, Faculty of Medicine, Saga 
      University, Saga, Japan.
FAU - Kimura, Shinya
AU  - Kimura S
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
FAU - Sueoka-Aragane, Naoko
AU  - Sueoka-Aragane N
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
FAU - Kawayama, Tomotaka
AU  - Kawayama T
AUID- ORCID: 0000-0002-9537-4229
AD  - Division of Respirology, Neurology, and Rheumatology, Department of Medicine, 
      Kurume University School of Medicine, Fukuoka, Japan.
CN  - Saga-naive COPD Physical Activity Evaluation (SCOPE) Study Investigator Group
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20211206
PL  - New Zealand
TA  - Int J Chron Obstruct Pulmon Dis
JT  - International journal of chronic obstructive pulmonary disease
JID - 101273481
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Benzoxazines)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Drug Combinations)
RN  - VD2YSN1AFD (olodaterol)
RN  - XX112XZP0J (Tiotropium Bromide)
SB  - IM
MH  - Administration, Inhalation
MH  - Adrenergic beta-2 Receptor Agonists/therapeutic use
MH  - Benzoxazines/adverse effects
MH  - Bronchodilator Agents/adverse effects
MH  - Drug Combinations
MH  - Forced Expiratory Volume
MH  - Humans
MH  - *Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy
MH  - *Sedentary Behavior
MH  - Tiotropium Bromide/adverse effects
MH  - Treatment Outcome
PMC - PMC8664652
OTO - NOTNLM
OT  - chronic obstructive pulmonary disease
OT  - long-acting beta 2 agonist
OT  - long-acting muscarinic antagonist
OT  - physical activity
OT  - sedentary time
COIS- Dr. Koichiro Takahashi received lecture fees from Nippon Boehringer Ingelheim and 
      AstraZeneca. Dr. Takashi Kinoshita received grants from Daiichi Sankyo. Dr. 
      Makoto Yoshida received lecture fees from AstraZeneca, GlaxoSmithKline, and 
      Novartis Pharma. Dr. Tomotaka Kawayama received grants from Novartis, and lecture 
      fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis Pharma, 
      Teijin Pharma and Home Healthcare, Sanofi, Kyorin Pharmaceutical, and MeijiSeika 
      Pharma. Dr. Hiroki Tashiro, Dr. Masaru Uchida, Dr. Go Kato, Dr. Yuki Kurihara, 
      Dr. Ayako Takamori, Dr. Ryo Tajiri, Dr. Hironori Sadamatsu, Dr. Atsushi 
      Kawaguchi, Dr. Shinya Kimura, and Dr. Naoko Sueoka-Aragane did not have any 
      conflicts of interests.
EDAT- 2021/12/16 06:00
MHDA- 2022/03/23 06:00
PMCR- 2021/12/06
CRDT- 2021/12/15 12:25
PHST- 2021/09/13 00:00 [received]
PHST- 2021/11/23 00:00 [accepted]
PHST- 2021/12/15 12:25 [entrez]
PHST- 2021/12/16 06:00 [pubmed]
PHST- 2022/03/23 06:00 [medline]
PHST- 2021/12/06 00:00 [pmc-release]
AID - 338560 [pii]
AID - 10.2147/COPD.S338560 [doi]
PST - epublish
SO  - Int J Chron Obstruct Pulmon Dis. 2021 Dec 6;16:3297-3307. doi: 
      10.2147/COPD.S338560. eCollection 2021.